The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis

DİNÇER İ., Ergin A., Kocagoz T.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, cilt.23, sa.4, ss.408-411, 2004 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 4
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1016/j.ijantimicag.2003.09.023
  • Dergi Adı: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.408-411
  • Anahtar Kelimeler: beta-lactam, beta-lactamases, M. tuberculosis, clavulanic acid, CLAVULANIC ACID, COMBINATION, AMOXICILLIN, SUSCEPTIBILITY, ANTIBIOTICS, ETHAMBUTOL
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

In vitro activity of beta-lactam antibiotics and their beta-lactamase inhibitor combinations were evaluated for their activity against clinical isolates of Mycobacterium tuberculosis and M. tuberculosis H37Ra. Agar dilution, the BACTEC 460 system and P-lactamase activity tests were used. Results using the BACTEC 460 and enzyme activity tests showed the best beta-lactamase inhibitor for M. tuberculosis H37Ra to be clavulanic acid. Cefazolin-clavulanic acid gave the lowest minimal inhibitory concentration (MIC) values using dilution tests and M. tuberculosis H37Ra. p-Lactam antibiotics were combined with clavulanic acid and tested for in vitro activity against 50 selected multidrug-resistant (MDR) and 50 susceptible clinical isolates. Seventy-four percent of the isolates were inhibited by cefazolin-clavulanic acid combination. These results suggested that an appropriate combination of p-lactam and p-lactamase inhibitors might be useful in the treatment of tuberculosis due to multidrug-resistant strains. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.